Japanese Approval Sought for Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

A sNDA seeking approval of enfortumab vedotin plus pembrolizumab for first-line use in patients with urothelial cancer has been submitted to Japan’s MHLW.

Related Keywords

Japan , ,European Medicines Agency ,Astellas Pharma Inc ,Japan Ministry Of Health ,Medicines Agency ,Enfortumab Vedotin ,Padcev ,Pembrolizumab ,Keytruda ,Urothelial Cancer ,Supplemental New Drug Application ,Ministry Of Health ,Labour ,End Welfare ,Ev 302 Keynote A39 Study ,